CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and
review of content for educational activities and report the following real or apparent conflicts of interest
for themselves (or their spouses/partners) that have been resolved through a peer review process:
John H Brebner, Anne Jacobson, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley,
Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall
and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC,
WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education
grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals
Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc,
Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our
educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Wolff — Consulting Fees: Eli Lilly and Company. Dr Berlin — Consulting Fees: Amgen Inc, AstraZeneca
Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech Inc, ImClone Systems Inc, Novartis Pharmaceuticals
Corporation, Pfizer Inc, Sanofi-Aventis. Dr Lenz — Consulting Fees: Bristol-Myers Squibb Company, Genentech Inc,
Merck KGaA, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Fees from
Non-CME Services Received Directly from Commercial Interest or Their Agents: Bristol-Myers Squibb Company,
Genentech Inc, ImClone Systems Inc, Merck KGaA, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Contracted
Research: Bristol-Myers Squibb Company, Celmed BioSciences Inc, Eisai Inc, Genentech Inc, ImClone Systems Inc,
Merck KGaA, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd.
This educational activity contains discussion of publisshed and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
